Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals says the FDA has approved...

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals says the FDA has approved Xarelto, an oral anticoagulant for the treatment of deep vein thrombosis and/or pulmonary embolism. The drug has a broad reimbursement base, encompassing more than 90% of commercial and Medicare health plan members.